Immune checkpoint inhibitor response in mismatch repair-deficient colorectal cancer and other solid tumors: is it truly disease-agnostic?

Notably, the authors included 27 cancer types in their cohort, where the most common cancers were endometrial (n=49), gastric (n=24), cholangiocarcinoma (n=22), pancreatic (n=22) and small intestine (n=19). Overall, the studies above clearly suggest that MMR-D in solid tumors is a predictor of respo...

Full description

Saved in:
Bibliographic Details
Published inColorectal cancer Vol. 9; no. 4
Main Author Sahin, Ibrahim Halil
Format Journal Article
LanguageEnglish
Published London Future Medicine Ltd 19.10.2020
Subjects
Blood-brain barrier
Brain cancer
Colorectal cancer
Deoxyribonucleic acid
disease-agnostic
DNA
Endometrial cancer
Genetic disorders
immune checkpoint inhibitor
Immunotherapy
ipilimumab
Lynch syndrome
Metastasis
MMR-D
Monoclonal antibodies
MSI-H
Mutation
nivolumab
Ovarian cancer
Pancreatic cancer
pembrolizumab
Small intestine
somatic mutations
Targeted cancer therapy
Tumors
United States > US
Online AccessGet full text

Cover

More Information
Summary:Notably, the authors included 27 cancer types in their cohort, where the most common cancers were endometrial (n=49), gastric (n=24), cholangiocarcinoma (n=22), pancreatic (n=22) and small intestine (n=19). Overall, the studies above clearly suggest that MMR-D in solid tumors is a predictor of response to immune checkpoint inhibitor therapy. [...]the ORR and durable responses were also similar to experiences with immune checkpoint inhibitors in patients with MMR-D colorectal cancer. Markedly, a study investigating the impact of BRCA gene alterations in solid tumor reported BRCA mutations in non-BRCA associated cancers may not have any clinical implication (17) suggesting highly actionable molecular alterations may have a distinct impact (or potentially no impact) on different types of cancer. [...]prospective studies are needed to evaluate the predictor role of characterization of T-cell infiltrate on immune checkpoint inhibitor response/resistance in cancer patients with MMR-D tumors.
ISSN:1758-194X
1758-1958
DOI:10.2217/crc-2020-0020